Drug Profile
ASP 3700
Alternative Names: ASP3700Latest Information Update: 02 Jul 2015
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 31 May 2015 Discontinued - Phase-I for Osteoarthritis (In volunteers) in United Kingdom (PO)
- 01 Oct 2014 Astellas Pharma Europe completes a phase I trial in Osteoarthritis (In volunteers) in the United Kingdom (NCT02155504)
- 12 May 2014 Phase-I clinical trials in Osteoarthritis in United Kingdom (PO)